Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

VALSARTAN FOR SYSTEM SUITABILITY CRS (0.202 MG)

VALSARTAN FOR SYSTEM SUITABILITY CRS (0.202 MG)

137862-53-4

DISCOVER
CIMETIDINE FOR SYSTEM SUITABILITY CRS (0.51 MG)

CIMETIDINE FOR SYSTEM SUITABILITY CRS (0.51 MG)

51481-61-9

DISCOVER
ORBIFLOXACIN IMPURITY MIXTURECRS (0.0008 MG)

ORBIFLOXACIN IMPURITY MIXTURECRS (0.0008 MG)

113617-63-3

DISCOVER
BUDESONIDE FOR SYSTEM SUITABILITY CRS (10 MG)

BUDESONIDE FOR SYSTEM SUITABILITY CRS (10 MG)

51333-22-3

DISCOVER
BERBERINE CHLORIDE CRS (20 MG)

BERBERINE CHLORIDE CRS (20 MG)

633-65-8

DISCOVER
DEXTROPROPOXYPHENE FOR SYSTEMSUITABILITY CRS - * NARC (DEXT

DEXTROPROPOXYPHENE FOR SYSTEMSUITABILITY CRS - * NARC (DEXT

1639-60-7

DISCOVER
HYDRASTINE HYDROCHLORIDE CRS (25 MG)

HYDRASTINE HYDROCHLORIDE CRS (25 MG)

5936-28-7

DISCOVER
IMMUNOGLOBULIN FOR ANTI-A, ANTI-B ANTIBODIES LIMIT TEST BRP

IMMUNOGLOBULIN FOR ANTI-A, ANTI-B ANTIBODIES LIMIT TEST BRP

NA

DISCOVER
APROTININ FOR SYSTEM SUITABILITY CRS (2.7 MG)

APROTININ FOR SYSTEM SUITABILITY CRS (2.7 MG)

9087-70-1

DISCOVER
DOCETAXEL FOR SYSTEM SUITABILITY CRS (15 MG)

DOCETAXEL FOR SYSTEM SUITABILITY CRS (15 MG)

148408-66-6

DISCOVER
IRBESARTAN IMPURITY A CRS (15MG)

IRBESARTAN IMPURITY A CRS (15MG)

NA

DISCOVER
MACROGOL POLY(VINYL ALCOHOL) GRAFTED COPOLYMER CRS (400 MG)

MACROGOL POLY(VINYL ALCOHOL) GRAFTED COPOLYMER CRS (400 MG)

96734-39-3

DISCOVER